Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Summit Therapeutics Inc. - Common Stock
(NQ:
SMMT
)
19.38
+0.46 (+2.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
↗
March 24, 2025
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.
Via
Benzinga
Is Summit Therapeutics a Millionaire Maker?
↗
March 23, 2025
Via
The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
This Unstoppable Biotech Stock Just Became an Even Better Buy
↗
March 19, 2025
Via
The Motley Fool
Is Summit Therapeutics a Millionaire Maker?
↗
February 09, 2025
Via
The Motley Fool
2 Stocks That Could Soar Again in 2025
↗
February 08, 2025
Via
The Motley Fool
Why Summit Therapeutics Rocketed 584% in 2024
↗
January 15, 2025
Via
The Motley Fool
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
March 17, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
↗
March 16, 2025
Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro...
Via
Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Why Summit Therapeutics Stock Was Winning This Week
↗
March 14, 2025
Via
The Motley Fool
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
↗
March 13, 2025
Via
The Motley Fool
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
↗
March 10, 2025
Via
The Motley Fool
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
February 28, 2025
Via
Benzinga
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown
↗
February 24, 2025
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.
Via
Stocktwits
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday?
↗
February 24, 2025
The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.
Via
Benzinga
Topics
Stocks
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
February 24, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
February 24, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Earnings Scheduled For February 24, 2025
↗
February 24, 2025
Via
Benzinga
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
↗
February 21, 2025
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Via
Benzinga
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
February 18, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
3 Stocks That Could Trounce the Market in 2025
↗
February 17, 2025
Via
The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'
↗
February 03, 2025
On CNBC's "Mad Money Lightning Round," Jim Cramer said Summit Therapeutics is "obviously just a very big spec."
Via
Benzinga
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?
↗
January 30, 2025
Via
The Motley Fool
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio?
↗
January 26, 2025
12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts.
Via
Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
↗
January 23, 2025
Via
The Motley Fool
Why Summit Therapeutics Stock Is Jumping Today
↗
January 21, 2025
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
↗
January 20, 2025
Via
Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
